Milestones
Established in September 2000, Shanghai Model Organisms Center Inc. has stayed true to its commitment to gene editing and the decoding of the language of life. Through our focus on the field of model organisms and our specialization in R&D, breeding and analysis of genetically-engineered animal models, we provide universities, research institutes, hospitals and pharmaceutical companies across the world with comprehensive, convenient and professional technical services and model resources.
Milestones
Founding of Shanghai Model Organisms Center in Sep. 2000
Established the R&D base for animal models of disease (biotechnology field) with support from the "863" program directed by the Ministry of Science and Technology in Nov. 2000
Completed construction of SPF animal rooms and embryo micro-manipulation experimental facilities in 2001
Successful generation of 1st SMOC transgenic mice in 2002
Successful generation of 1st SMOC knockout mice in 2003
Included as one of the first R&D public service platforms in Shanghai in 2007
Establishment of zebrafish research platform in 2008
Establishment of C. elegans research platform in 2010
Recognized as Shanghai Professional Technical Service Platform for Animal Models in 2011
Recognized as Shanghai High and New Technology Enterprise (HNTE) in 2011
Recognized as Shanghai Engineering and Technological Research Center for Animal Models in 2012
Obtained AAALAC accreditation in 2012
Recognized as Shanghai Professional Technical Service Platform for Comparative Medicine in 2015
Series A funding in 2015
Transformed into a joint-stock company and renamed as Shanghai Model Organisms Center, Inc. in Jun. 2016
Completed NEEQ listing, stock code 839728 in Nov. 2016
Recognized as Shanghai Science and Technology Little Giant Enterprise in 2017
Brand upgrading in 2018
Establishment of preclinical efficacy evaluation service platform in 2019
Series B funding in 2020
SMOC(stock code:688265) launched into SSE STAR Market in 2021
Popular articles
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreAfter the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
Learn more